Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer’s disease detection and staging July 10, 2026 06:11 ET  | Source: Alamar Biosciences, Inc. Fremont, CA, July 10, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that […]

Global CRO highlights multi-regional trial delivery, early-phase Australia advantages, and expanding support for biotech sponsors across Asia and China July 09, 2026 19:59 ET  | Source: Avance Clinical ADELAIDE, Australia, July 10, 2026 (GLOBE NEWSWIRE) — Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced its participation in BIO Asia–Taiwan 2026, taking place 15–19

July 09, 2026 08:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations

July 07, 2026 09:23 ET  | Source: Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review

July 07, 2026 09:12 ET  | Source: Alamar Biosciences, Inc. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program Data to

July 07, 2026 09:07 ET  | Source: King Faisal Specialist Hospital & Research Centre JEDDAH, Kingdom of Saudi Arabia, July 07, 2026 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre in Jeddah has successfully developed and implemented the world’s first protocol of its kind, using an algorithm to accurately estimate the expected stem cell yield

Novo Nordisk will conduct a non-exclusive internal evaluation of semaglutide implants prepared by Vivani July 07, 2026 07:35 ET  | Source: Vivani Medical, Inc. ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting drug implants, today announced the signing of a

July 07, 2026 07:00 ET  | Source: Teva Pharmaceutical Industries Ltd Teva will hold an investor call and live webcast today,Tuesday, July 7, 2026, at 8:00 a.m. ET to discuss these data. TEL AVIV, Israel, July 07, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to advance its TEV-’408, an

July 06, 2026 10:00 ET  | Source: Aztiq Consulting ehf. REYKJAVIK, Iceland, July 06, 2026 (GLOBE NEWSWIRE) — Aztiq today announced the promotion of David Olafsson, Danny Major and Eunsun Choi to Partner, recognizing their significant contributions to Aztiq’s growth, investment activities and long-term value creation across the healthcare ecosystem. Aztiq is an investment company focused on

July 02, 2026 10:45 ET  | Source: Allwyn The F1® Allwyn Global Community Award 2026 trophy presented to Jonny Wright and Laura Walsh from winning local charity Starlight Children’s Foundation at the FORMULA 1® PIRELLI BRITISH GRAND PRIX 2026 at Silverstone, UK. SILVERSTONE, United Kingdom, July 02, 2026 (GLOBE NEWSWIRE) — Starlight Children’s Foundation has been named

July 01, 2026 20:43 ET  | Source: Junshi Biosciences SHANGHAI, July 01, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the company has recently entered into a license agreement with Fosun Wanbang Pharma

New collaboration delivers streamlined integration from drug substance to drug product, including sterile fill-finish and device assembly for clinical programs. June 30, 2026 12:00 ET  | Source: AGC Biologics, Inc. SEATTLE, June 30, 2026 (GLOBE NEWSWIRE) — Drug developers have a new, optimized option for U.S.-based manufacturing, as AGC Biologics enters a strategic partnership with Pyramid Pharma

June 30, 2026 08:30 ET  | Source: Kyowa Kirin PRINCETON, N.J., June 30, 2026 (GLOBE NEWSWIRE) — Researchers at the World Congress of Cutaneous Lymphoma 2026 presented two indirect treatment comparison (ITC) analyses examining the impact of mogamulizumab on long-term outcomes, including overall survival (OS), in patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome

June 29, 2026 09:00 ET  | Source: Optimi Health Corp. Optimi’s 5mg psilocybin capsules are prescribed in Australia for treatment-resistant depression.The export marks Optimi’s third commercial shipment since launching the 5mg psilocybin capsules in September 2025. VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the “Company” or “Optimi”), a

June 29, 2026 08:30 ET  | Source: Kyowa Kirin PRINCETON, N.J., June 29, 2026 (GLOBE NEWSWIRE) — Kyowa Kirin, Inc., a wholly owned subsidiary of Kyowa Kirin Co. Ltd (TSE: 4151), today announced positive results from PROSPER, a real-world observational study of mogamulizumab in adults with mycosis fungoides (MF) or Sézary syndrome (SS). In the study, patients